Articles

The advent of next-generation sequencing (NGS) technologies has revolutionized the way we approach and utilize molecular diagnostic testing in oncology. Read More ›

The advent of next-generation sequencing (NGS) technologies has revolutionized the way we approach and utilize molecular diagnostic testing in oncology. Read More ›

The clinical application of assays that utilize next-generation sequencing (NGS) technology is accelerating rapidly in the field of oncology. Read More ›

Following the advent of molecularly targeted agents, and more recently, immunotherapy, over the past few decades, we have witnessed dramatic changes in the treatment paradigms for many types of cancer. Read More ›

On March 8, 2019, the FDA granted accelerated approval to Genentech’s Tecentriq (atezolizumab), in combination with nab-paclitaxel (Abraxane), for the treatment of PD-L1–positive unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). This marks the first time an immunotherapy drug has been granted approval for the treatment of any form of breast cancer. Read More ›

Approvals for new delivery methods for Herceptin and Cinvanti, and a new indication for Lonsurf close out the month of February in the FDA’s oncology-related activity. Read More ›

The February issue of The Oncology Nurse-APN/PA (TON) is packed with important news and insights for today’s oncology nurse. We start off our coverage with a profile of Rutgers Cancer Institute of New Jersey, New Brunswick, which, in collaboration with RWJBarnabas Health, provides patients with cancer many advanced treatment options. This interview is with Renee Kurz, DNP, RN, FNP-BC, AOCNP, Associate Director, Statewide Research, and Patient and Nursing Education, who was excited to discuss the center’s accreditation as a Provider of Continuing Nursing Education by the American Nurses Credentialing Center. Dr Kurz explained how this accreditation has allowed Rutgers Cancer Institute of New Jersey to offer nurses high-quality oncology education to meet certification or licensure requirements. She also discussed how these educational offerings benefit patients (click here). Read More ›

Rutgers Cancer Institute of New Jersey, New Brunswick, in collaboration with RWJBarnabas Health, offers patients many advanced cancer treatment options, including immunotherapy, precision medicine, preventive services, and education. In 2018, Rutgers Cancer Institute of New Jersey earned accreditation as a Provider of Continuing Nursing Education by the American Nurses Credentialing Center (ANCC), which recognizes high-quality continuing nursing education, interprofessional continuing education, transition to practice programs, and skills-based competency programs. Read More ›

The large, randomized TAM-01 clinical trial demonstrated that 5 mg daily of tamoxifen for 3 years halved the risk for recurrence of breast intraepithelial neoplasia—atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), and lobular carcinoma in situ—in women after surgery and reduced the risk for new contralateral breast cancer by 75% compared with placebo. Read More ›

San Antonio, TX—An interim analysis of a randomized clinical trial showed that a lifestyle intervention aimed at weight loss achieved approximately a 1-kg weight loss in patients with early breast cancer who received chemotherapy, whereas patients in the control group gained approximately 1 kg over the course of the study. Read More ›